InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Ellison Mark Jason Heath, Directeur du Développement. Officer active across 1 company, notably Opiant Pharmaceuticals, INC.. Aggregated, 6 disclosures have been published. Breakdown: 0 buy · 3 sells. Total volume traded: €55k. Activity tracked since 4 January 2022. The latest transaction was disclosed on 2 March 2023 (Disposition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Ellison Mark Jason Heath
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
7,015 shares@ US$20.0070.7% of flowCommon StockSEC:0001385508-23-000067:0
610 shares@ US$20.266.1% of flowCommon StockSEC:0001385508-23-000033:0
469 shares@ US$20.204.8% of flowCommon StockSEC:0001385508-23-000022:0
1,806 shares@ US$20.2018.5% of flowCommon StockSEC:0001385508-23-000013:0
2,000 shares0Common StockSEC:0001385508-22-000104:0
12,000 shares0Common StockSEC:0001385508-22-000011:0
6 of 6 declarations
About Ellison Mark Jason Heath
Mark Jason Heath Ellison is the Chief Development Officer at Opiant Pharmaceuticals, Inc. In this role, he is responsible for the business development strategy and growth of the company in the pharmaceutical sector. His expertise in product development and project management is essential for innovation and success at Opiant Pharmaceuticals. Mark Jason Heath Ellison plays a key role in expanding the company's operations.
